A rapid and sensitive LC-MS/MS method for determination of valsartan in human plasma

Abstract

Abstract: AIM: To establish a rapid and sensitive LC-MS/MS method for determination of valsartan in human plasma.METHODS: The prepared analytes were separated on an ODS column using mobile phase of acetonitrile and 1‰ methanoic acid (70∶30). Valsartan and irbesartan were detected by multiple reaction monitoring (MRM) mode after ionized by ESI source. The transitions of m/z436.3→235.2 and m/z 429.4→207.2 were used to quantify valsartan and irbesartan, respectively.RESULTS: The method was linear in the range of 24.2-3100.0 μg/L for valsartan. The intra-day mean precision and inter-day mean accuracy precision was not more than 15%.CONCLUSION: The method is rapid and sensitive, and it's adaptive for clinic pharmacokinetic evaluation of valsartan.

Key words: Valsartan, LC-MS/MS, Bioequivalence

CLC Number:

R969.1

LI Ling, TAN Zhi-rong, CHEN Yao, ZHOU Gan, GUO Dong, YAN Jin, YANG Guo-ping, OUYANG Dong-sheng. A rapid and sensitive LC-MS/MS method for determination of valsartan in human plasma[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(7): 809-813.

References

[1] 李纳新, 董敬远, 付志, 等. 国产与进口缬沙坦治疗原发性高血压的药物经济学评价[J]. 中国实用神经疾病杂志, 2008, 11(5): 126-127.
[2] Li H, Wang Y, Jiang Y, et al. A liquid chromatography/tandem mass spectrometry method for the simultaneous quantification of valsartan and hydrochlorothiazide in human plasma[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2007, 852(1/2) :436-442.
[3] Selvan PS, Gowda KV, Mandal U, et al. Simultaneous determination of fixed dose combination of nebivolol and valsartan in human plasma by liquid chromatographic-tandem mass spectrometry and its application to pharmacokinetic study[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2007, 858(1/2) :143-150.
[4] Koseki N, Kawashita H, Hara H, et al. Development and validation of a method for quantitative determination of valsartan in human plasma by liquid chromatography-tandem mass spectrometry[J]. J Pharm Biomed Anal, 2007, 43(5) : 1769-1774.
[5] 赵荣伟, 俞佳. 荧光检测法测定人血浆中缬沙坦的浓度[J].中国临床药理学与治疗学, 2005, 10(9): 1038-1040.
[6] 张锋. 反相高效液相色谱法研究缬沙坦分散片人体生物等效性[J]. 海峡药学, 2008, 20(5): 104-106.
[7] 徐燕丰, 曹文, 林欣, 等. 高效液相色谱法测定血浆缬沙坦浓度[J]. 中国药理学通报, 2002, 18(5): 586-588.
[8] 黄一玲, 田蕾, 李一石, 等. 缬沙坦3种制剂的健康人体生物等效性研究[J]. 中国新药与临床杂志, 2003, 22(6): 341-344.
[9] 黄建耿, 斯陆勤, 李高. 复方缬沙坦分散片在健康人体内的药物动力学[J].中国医药工业杂志, 2007, 38(11): 780-783.
[10] 许长江, 刘骁, 王海学, 等. 缬沙坦胶囊在人体的药物动力学及相对生物利用度[J]. 中国临床药学杂志, 2002, 11(2): 91-94.
[11] 李艳萍, 阳利. HPLC荧光法测定缬沙坦的血药浓度[J]. 医学临床研究, 2006, 23(10):1684-1685.
[12] 李扬, 陈今扬, 王德志. 高效液相色谱法测定人血浆中缬沙坦、氢氯噻嗪浓度[J]. 中国新药杂志, 2005, 14(11): 1335-1338.

[1]	YAN Qiangyong, XIANG Daxiong, ZHU Ronghua, YANG Lingfeng, YANG Xiding, LI Jingjing, FAN Xiao, LIU Sai, XIONG Shoujun, FANG Pingfei. Bioequivalence study of cinacalcet hydrochloride tablets in healthy Chinese volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 171-177.
[2]	LI Xuejing, JIANG Jinping, LI Sining, WAN Linfei, ZHOU Xiangxiang, YANG Lian, LAN Ke. A bioequivalence study of generic and brand clozapine in schizophrenic patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1121-1130.
[3]	LIU Min, KONG Xiang, ZHANG Ye, GU Yifei, XIANG Xuemei, HUANG Kai. Safety analysis on bioequivalence studies of orally inhaled drug products in healthy Chinese subjects#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1131-1138.
[4]	YANG Sheng, WANG Deguo. Effects of sakubatril valsartan combined with dagliflozin in the treatment of patients with HFrEF and the effect on serum cTnⅠ and BNP levels [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1010-1015.
[5]	GU Yifei, CHU Nannan, HUANG Kai, QUE Linling, ZHANG Jisheng, XIANG Xuemei, HE Qing. Application and progress of pharmacodynamics study in bioequivalence evaluation of orally inhaled drug products [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 822-833.
[6]	WU Juan, WANG Zhiqiang, ZHOU Renpeng, YANG Jingjing, QIN Huiling, ZHANG Qian, LU Chao, HU Wei. Bioequivalence trial of fasting oral sorafenib tosylate tablets in healthy Chinese subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 281-286.
[7]	SHI Gexin, CHONG Rui, HE Kun, WU Haitang, ZHOU Yu, DUN Zhongjun, WEN Qing, ZHANG Jiguo, ZHANG Rong. A fully replicated crossover bioequivalence study of mycophenolate mofetil capsules in Chinese healthy male subjects under fasting and fed conditions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1255-1263.
[8]	GAO Rong, MA Yazhong, ZHAO Haixia, WANG Zhaoyuan, ZHANG Weihong, YUAN Hailong. Bioequivalence of amlodipine besylate tablets in Chinese healthy subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 56-62.
[9]	HU Yin, YANG Dandan, XU Yichao, SHAO Rong, RUAN Zourong, JIANG Bo, CHEN Jinliang, LOU Honggang. Application of artificial neural network model in bioequivalence study of candesartan cilexetil tablets [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 63-69.
[10]	CAI Mingmin, SHAO Jing, TANG Lu, SUN Qiuyue, DOU Ting, QIAN Wei, WANG Huiping. Bioequivalence study of buthlphthalide injection in Chinese healthy volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 70-76.
[11]	ZHENG Binjie, LIU Na, ZENG Xiangchang, HUANG Xinyi, CHEN Lulu, OU-YANG Dongsheng. Effects of gut microbiota on pharmacokinetics and its consideration in the evaluation of the consistency of quality and efficacy of generic drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 662-671.
[12]	SUN Yuchen, LIU Yinhui, ZHANG Xian, YUAN Tong, JING Mengyao, ZAHNG Xinyu, YANG Jin. Exploration of screening criteria for healthy volunteers in human bioequivalence clinical trials [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 714-720.
[13]	XU Guofang, ZHANG Sisen, LIU Ping, MEI Jiazhuan, LIU Weiwei, LIU Ya'ou, QI Qi. Population pharmacokinetics of capecitabine in Chinese breast cancer patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 552-559.
[14]	MA Hong, LIU Jingyuan, JIN Hao, CHEN Yong, WANG Bo, LIU Wanhui, SI Duanyun, XIA Yuanyuan. Quantification of ambrisentan in human plasma by LC-MS/MS and its pharmacokinetic application [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 382-388.
[15]	LI Xiaomin, JIN Hao, ZHOU Wenzhi, YANG Hanyue, ZOU Ting, GUO Jie, XU Pingsheng. Bioequivalence of metformin hydrochloride sustained-release tablets in healthy subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 408-413.